Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • MB11 (Proposed Nivolumab Biosimilar)Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Active Trials
1(100%)

Phase Distribution

Phase 3
1
100%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

1

all time

Status Distribution
Active(1)

Detailed Status

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
1
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

recruiting1100%

Recent Activity

1 active trials
Showing 1 of 1
recruitingphase_3

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

NCT07221734

Clinical Trials (1)

Showing 1 of 1 trials
NCT07221734Phase 3

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

Recruiting

All 1 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
1